Literature DB >> 23707466

Characterization and aerosol dispersion performance of advanced spray-dried chemotherapeutic PEGylated phospholipid particles for dry powder inhalation delivery in lung cancer.

Samantha A Meenach1, Kimberly W Anderson, J Zach Hilt, Ronald C McGarry, Heidi M Mansour.   

Abstract

Pulmonary inhalation chemotherapeutic drug delivery offers many advantages for lung cancer patients in comparison to conventional systemic chemotherapy. Inhalable particles are advantageous in their ability to deliver drug deep in the lung by utilizing optimally sized particles and higher local drug dose delivery. In this work, spray-dried and co-spray dried inhalable lung surfactant-mimic PEGylated lipopolymers as microparticulate/nanoparticulate dry powders containing paclitaxel were rationally designed via organic solution advanced spray drying (no water) in closed-mode from dilute concentration feed solution. Dipalmitoylphosphatidylcholine (DPPC) and dipalmitoylphosphatidylethanolamine poly(ethylene glycol) (DPPE-PEG) with varying PEG chain length were mixed with varying amounts of paclitaxel in methanol to produce co-spray dried microparticles and nanoparticles. Scanning electron microscopy showed the spherical particle morphology of the inhalable particles. Thermal analysis and X-ray powder diffraction confirmed the retention of the phospholipid bilayer structure in the solid-state following spray drying, the degree of solid-state molecular order, and solid-state phase transition behavior. The residual water content of the particles was very low as quantified analytically Karl Fisher titration. The amount of paclitaxel loaded into the particles was quantified which indicated high encapsulation efficiencies (43-99%). Dry powder aerosol dispersion performance was measured in vitro using the Next Generation Impactor (NGI) coupled with the Handihaler dry powder inhaler device and showed mass median aerodynamic diameters in the range of 3.4-7 μm. These results demonstrate that this novel microparticulate/nanoparticulate chemotherapeutic PEGylated phospholipid dry powder inhalation aerosol platform has great potential in lung cancer drug delivery.
Copyright © 2013 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Biocompatible biodegradable lipopolymers; Dry powder inhaler (DPI); Lung surfactant; Nanomedicine; Nanotechnology; Respiratory drug delivery

Mesh:

Substances:

Year:  2013        PMID: 23707466      PMCID: PMC5818719          DOI: 10.1016/j.ejps.2013.05.012

Source DB:  PubMed          Journal:  Eur J Pharm Sci        ISSN: 0928-0987            Impact factor:   4.384


  38 in total

Review 1.  Drug properties affecting aerosol behavior.

Authors:  S Suarez; A J Hickey
Journal:  Respir Care       Date:  2000-06       Impact factor: 2.258

Review 2.  Advancements in dry powder delivery to the lung.

Authors:  Yoen-Ju Son; Jason T McConville
Journal:  Drug Dev Ind Pharm       Date:  2008-09       Impact factor: 3.225

Review 3.  Recent advances in pulmonary drug delivery using large, porous inhaled particles.

Authors:  D A Edwards; A Ben-Jebria; R Langer
Journal:  J Appl Physiol (1985)       Date:  1998-08

Review 4.  Development of inhalational agents for oncologic use.

Authors:  S Sharma; D White; A R Imondi; M E Placke; D M Vail; M G Kris
Journal:  J Clin Oncol       Date:  2001-03-15       Impact factor: 44.544

Review 5.  Formulations for pulmonary administration of anticancer agents to treat lung malignancies.

Authors:  Thiago C Carvalho; Simone R Carvalho; Jason T McConville
Journal:  J Aerosol Med Pulm Drug Deliv       Date:  2011-03-16       Impact factor: 2.849

Review 6.  Paclitaxel: a review of adverse toxicities and novel delivery strategies.

Authors:  Neena I Marupudi; James E Han; Khan W Li; Violette M Renard; Betty M Tyler; Henry Brem
Journal:  Expert Opin Drug Saf       Date:  2007-09       Impact factor: 4.250

7.  Phospholipid-induced in vivo particle migration to enhance pulmonary deposition.

Authors:  Sudipta Ganguly; Vikas Moolchandani; Joseph A Roche; Paul S Shapiro; Shailaja Somaraju; Natalie D Eddington; Richard N Dalby
Journal:  J Aerosol Med Pulm Drug Deliv       Date:  2008-12       Impact factor: 2.849

Review 8.  Materials for pharmaceutical dosage forms: molecular pharmaceutics and controlled release drug delivery aspects.

Authors:  Heidi M Mansour; Minji Sohn; Abeer Al-Ghananeem; Patrick P Deluca
Journal:  Int J Mol Sci       Date:  2010-09-15       Impact factor: 5.923

9.  Development of highly porous large PLGA microparticles for pulmonary drug delivery.

Authors:  Yan Yang; Nimisha Bajaj; Peisheng Xu; Kimberly Ohn; Michael D Tsifansky; Yoon Yeo
Journal:  Biomaterials       Date:  2009-01-08       Impact factor: 12.479

10.  Design, physicochemical characterization, and optimization of organic solution advanced spray-dried inhalable dipalmitoylphosphatidylcholine (DPPC) and dipalmitoylphosphatidylethanolamine poly(ethylene glycol) (DPPE-PEG) microparticles and nanoparticles for targeted respiratory nanomedicine delivery as dry powder inhalation aerosols.

Authors:  Samantha A Meenach; Frederick G Vogt; Kimberly W Anderson; J Zach Hilt; Ronald C McGarry; Heidi M Mansour
Journal:  Int J Nanomedicine       Date:  2013-01-15
View more
  20 in total

1.  Distribution and Cellular Uptake of PEGylated Polymeric Particles in the Lung Towards Cell-Specific Targeted Delivery.

Authors:  Tammy W Shen; Catherine A Fromen; Marc P Kai; J Christopher Luft; Tojan B Rahhal; Gregory R Robbins; Joseph M DeSimone
Journal:  Pharm Res       Date:  2015-05-23       Impact factor: 4.200

Review 2.  Novel Approaches for the Treatment of Pulmonary Tuberculosis.

Authors:  Zhi Ming Tan; Gui Ping Lai; Manisha Pandey; Teerapol Srichana; Mallikarjuna Rao Pichika; Bapi Gorain; Subrat Kumar Bhattamishra; Hira Choudhury
Journal:  Pharmaceutics       Date:  2020-12-10       Impact factor: 6.321

3.  Microparticulate/Nanoparticulate Powders of a Novel Nrf2 Activator and an Aerosol Performance Enhancer for Pulmonary Delivery Targeting the Lung Nrf2/Keap-1 Pathway.

Authors:  Priya Muralidharan; Don Hayes; Stephen M Black; Heidi M Mansour
Journal:  Mol Syst Des Eng       Date:  2016-01-27

4.  High-performing dry powder inhalers of paclitaxel DPPC/DPPG lung surfactant-mimic multifunctional particles in lung cancer: physicochemical characterization, in vitro aerosol dispersion, and cellular studies.

Authors:  Samantha A Meenach; Kimberly W Anderson; J Zach Hilt; Ronald C McGarry; Heidi M Mansour
Journal:  AAPS PharmSciTech       Date:  2014-08-20       Impact factor: 3.246

5.  Development and physicochemical characterization of acetalated dextran aerosol particle systems for deep lung delivery.

Authors:  Zimeng Wang; Sweta K Gupta; Samantha A Meenach
Journal:  Int J Pharm       Date:  2017-04-24       Impact factor: 5.875

6.  Nanocomposite microparticles (nCmP) for the delivery of tacrolimus in the treatment of pulmonary arterial hypertension.

Authors:  Zimeng Wang; Julie L Cuddigan; Sweta K Gupta; Samantha A Meenach
Journal:  Int J Pharm       Date:  2016-08-26       Impact factor: 5.875

7.  Synthesis and Characterization of Nanocomposite Microparticles (nCmP) for the Treatment of Cystic Fibrosis-Related Infections.

Authors:  Zimeng Wang; Samantha A Meenach
Journal:  Pharm Res       Date:  2016-04-18       Impact factor: 4.200

8.  Advanced spray dried proliposomes of amphotericin B lung surfactant-mimic phospholipid microparticles/nanoparticles as dry powder inhalers for targeted pulmonary drug delivery.

Authors:  Alexan I Gomez; Maria F Acosta; Priya Muralidharan; Jason X-J Yuan; Stephen M Black; Don Hayes; Heidi M Mansour
Journal:  Pulm Pharmacol Ther       Date:  2020-10-31       Impact factor: 3.410

9.  Inhalable PEGylated Phospholipid Nanocarriers and PEGylated Therapeutics for Respiratory Delivery as Aerosolized Colloidal Dispersions and Dry Powder Inhalers.

Authors:  Priya Muralidharan; Evan Mallory; Monica Malapit; Don Hayes; Heidi M Mansour
Journal:  Pharmaceutics       Date:  2014-06-20       Impact factor: 6.321

10.  Development of three-dimensional lung multicellular spheroids in air- and liquid-interface culture for the evaluation of anticancer therapeutics.

Authors:  Samantha A Meenach; Alexandra N Tsoras; Ronald C McGarry; Heidi M Mansour; J Zach Hilt; Kimberly W Anderson
Journal:  Int J Oncol       Date:  2016-02-04       Impact factor: 5.650

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.